
Chronic myelomonocytic leukaemia program in Pharmaceutical Benefits Scheme (PBS) 012-22062453

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised azacitidine and
decitabine+cedazuridine for patients with chronic myelomonocytic
leukaemia (CMML).

Chronic myelomonocytic leukaemia and listing dates

Chronic myelomonocytic leukaemia is a chronic blood cancer in which a
person’s bone marrow creates too many monocytes, a type of white blood
cell.

Listing dates are:

-   azacitidine - 1 February 2011, and
-   decitabine+cedazuridine - 1 October 2022

For more information, see Written Authority Required Drugs.

Enquiries

-   Transfer enquiries about prescription arrangements for azacitidine
    to the PBS Complex Drugs Programs team and choose the option
    relevant to the condition treated
-   Transfer enquiries about prescription arrangements for
    decitabine+cedazuridine to PBS authority approvals

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
